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INTRODUCTION 
Hinton and Peppy et.al described Allergic bronchopulmonary 
aspergillosis as a disease characterised by hypersensitivity to Aspergillus 
antigen occurring in immunocompetent persons ,associated with 
spectrum of disease like steroid dependent asthma and cystic fibrosis. 
 Patterson and Greenberg did pioneering studies in the prevalence 
and pathogenesis of allergic bronchopulmonary aspergillosis and 
proposed diagnostic criteria. 
It often masquerades as bronchial asthma with frequent 
exacerbations and difficulty in tapering steroids. It is one of the 
progressive disease not only causing serological change but also spectrum 
of changes in the parenchyma and airways characterized by central 
bronchiectasis and fleeting opacities.  
   By identifying and classifying this disease, we can prevent 
worsening of asthma and also can retard the relentless progression of 
allergic bronchopulmonary aspergillosis. 
On chest radiograph, fleeting opacities may resemble pulmonary 
tuberculosis resulting in inappropriate treatment as drug resistant 
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tuberculosis. To diagnose ABPA as a cause of the radiological shadow, 
high index of suspicion is warranted.  
Genetic susceptibility has also been documented in patients with 
HLA- DR2 and HLA-DR5 showing increased propensity to Allergic 
Bronchopulmonary Aspergillosis patients with HLA DRQ2 have reduced 
susceptibility. 
  It is imperative to consider ABPA in patients who are resistant and 
refractory to standard protocol based treatment for bronchial asthma. 
The importance lies on the fact that, on correct identification and with 
appropriate treatment, patients can be relieved of their ordeal .Thereby 
the patient’s quality of life can be improved with increased disease free 
interval and reduced workplace absenteeism. 
In this study we attempt to diagnose and stage ALLERGIC 
BRONCHOPULMONARY ASPERGILLOSIS its prevalence and its association 
with bronchial asthma, Asthmatics who were refractory to protocol based 
treatment and clinical impact of ABPA over Asthma patients. 
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AIMS AND OBJECTIVES 
1.To findout the prevalence of allergic broncho pulmonary aspergillosis in 
patients with resistant asthma. 
2.To identify the clinical and laboratory pointers of  ABPA. 
3.To identify the effect of ABPA and and its treatment on the course of  
resistant asthma. 
 
OBJECTIVES 
Primary Objective is to study about , 
 “THE PREVALENCE AND CLINICAL IMPACT OF ALLERGIC 
BRONCHOPULMONARY ASPERGILLOSIS IN RESISTANT ASTHMATICS ON 
TREATMENT IN THE RAJIV GANDHI GOVERNMENT GENERAL HOSPITAL “ 
 
Secondary Objectives are 
a) To assess the  disease severity and treatment modification for 
control in asthmatics due to the coexistence of allergic broncho 
pulmonary aspergillosis 
b) To assess the prognosis periodically and at the end of 6 months 
after the modification of treatment. 
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Study design 
The study is a Prospective , uncontrolled and non-blinded study done in 
both out-patients and in-patients. 
 
Period of study: 6 months 
 
Ethical Clearance: 
Approved by the ethical committee of Madras Medical college  
  
Consent 
Written informed consent from all patients or their relatives 
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REVIEW OF LITERATURE 
 INTRODUCTION 
Allergic broncho pulmonary aspergillosis is a disease of  individuals 
with atopic  asthma , which is steroid responsive. It is characterised by 
mild wheeze , golden brown sputum with mucus plug  into proximal 
airways causing  disease spectrum varying  from mild exacerbation of the 
disease to  severe respiratory failure and pathological changes like 
terminal musculo cartilaginous destruction , central Bronchiectesis and 
upper lobe parenchymal disease .Though   this disease is considered as a  
rare entity , most of the time what we  see is the tip of the iceberg where 
most of the disease is submerged among the difficult to control asthma 
and  and a small number of group of people with cystic fibrosis  
 
 HISTORY; 
It was first reported in Great Britain  in late 18th century and  
reexplored  by HINTON in 19 50s  and his co workers  who described the 
universal nature of the causative organism  It is still designated as 
idiopathic by HINTON et al  and revised by PEPYs and coworkers as allergic 
inflammatory pulmonary disease to aspergillus species and mycelia 
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colonised in the bronchi. The  disease spectrum occurring in difficult  to 
treat asthma  patients and about 7 to 15 percent of steroid responsive 
asthma affecting age group of  early20’s to 40 years  of people.  
 
DEFINTION 
Allergic bronchopulmonary aspergillosis is a hypersensitive disorder 
caused by a fungus aspergillus species commonly fumigatus ,flavus,niger 
etc., occurring in asthmatic and  ,atopy prone  individuals or those  with 
cystic fibrosis triggerred by an exposure to aspergillus spores  colonising 
the proximal airways and the their mucus  plugs in the persons who are 
immunocompetent  with little or no  tissue invasion . It is a Th2 mediated 
reaction with eosinophilic response and inflammation 
It is a disease manifesting commonly in difficult to treat asthma patients  
and cystic fibrosis where there is impaired mucosal clearance of the 
secretion  with sprouting of spores into mycelia which colonise the 
bronchi and mucus plugs.causing  
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1. Asymptomtic course 
2. Cough with wheeze ,golden brownish productive sputum that contains 
the organism ,low grade fever, myalgia and other constitutional 
symptoms. 
3. During the prolonged unrecognised course patients can be affected by 
collapse, consolidation without any volume loss or chronic fibrotic 
pulmonary parenchymal lesion like scarring 
4. Affected individuals suffers recurrent and frequent exacerbations, 
cystic, cylindrical, central or proximal bronchiectasis. 
 
Criteria for the diagnosis of ABPA 
  
1.  Known Asthmatic 
2. Skin prick test  positive to Aspergillus sp 
3. Raised serum IgE concentration (>1000 ng/ml) 
4. Elevated serum specific IgE levels 
5. Serum Precipitin level 
6. Absolute Eosinophil count 
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7. Chest X ray evidence 
8. Proximal  Bronchiectasis 
MORTALIY AND MORBIDTY: 
Though the mortality is less likely and occurs only in extreme illness. 
Causes  leading on to mortality were enlisted as  
 Resistant secondary bacterial infections with organisms like 
pseudomonas in the preexisting dilated airways 
 Progressive desaturation and respiratory failure 
 Corpulmonale 
Significant morbidity can be noted due the following reasons 
 It is due to poor asthma control. 
 Difficulty in tapering  off corticosteroids and other drugs 
 Airways destruction like bronchiectasis 
 Parenchymal scarring  
 
FREQUENCY 
How common the ABPA is still a subject of research with various 
statistical datas from various corners of the world. Yet  unique and 
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concrete criterion are lagging to suspect and to coin the patient as ABPA 
leaving the disease submerged in refractory asthma 
Positive intradermal test for aspergillosis is seen in 24%of 
asthmatics and nearly half of the patients with cystic fibrosis ,8 to 16 % of 
the steroid dependent asthma who have associated  central 
bronchiectasis. 
 One another statistical study conducted in India by using 
Rosenberg criteria gives 52% positivity in 356 asthmatic individuals 
 
GENETIC PREDISPOSTION: 
Human Leukocyte antigen major histocompatibility complex mainly 
DR 4 DR5, DR 2 are associated with increased incidence of the disease 
where as DRQ2 has a protective role. 
 
DEMOGRAPHY 
Occurence of allergic bronchopulmonary aspergillosis has been 
documented in 2nd , 3rd and 4th decades, though it may occur in any 
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extremes of life and cases have been reported in these age groups .ABPA 
is under reported despite its  large occurrence . 
Puzzling and confusing  factors are the  principal manifestation  and 
hence there is remarkable misperception with other clinical conditions 
and infectious diseases 
  Migratory shadows disappear once the patients coughs out  and 
hence this roentgenographic shadows are  often  misleading and treated 
as some other diseases especially as resistant tuberculosis allowing the 
disease to progress with its image mimicry. 
The disease if not doubted is hard to diagnose and diagnosis at an 
early stage  is mandatory because ABPA may leave  significant structural 
damage as the immunity wanes off over the course  of time. 
Outpatients attending the emergency outpatient departments with 
a wheeze and cough are given symptomatic treatment and disposed with 
drugs and injections In  these patients ,the follow up is lost, owing to the 
relief offered temporarily by the medications given to them . Imaging and 
routine investigations were not done in those patients. Suspiscion was not 
posed due to decreased awareness and also the cost benefit ratio of 
those patients attending at odd hours of emergency ops. 
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GENDER 
  Incidence is more or less equal in both the genders .Atopy plays a 
major role in females. Occupational exposure plays a major role in 
females but there is no genetic or hormonal evidence for sex predilection. 
Prevalence  in various ethnic group is not documented. 
 
OCCUPATION 
The allergen is ubiquitous but certain occupation are at increased 
risk  like farmers, wooden workers, sewage workers etc., Special emphasis 
of ABPA over asthma in occupational context in atopy in individuals is not 
like that in exercise induced asthma. 
 
SOCIOECONOMIC STATUS 
Low socioeconomic income group are more at risk  
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SOURCE 
Chopped grasses , sewage , wet basement of buildings are the 
household sources. It is  universally present in paddy fields and 
decomposing vegetables.[6]  
MASON et al. says saprophytic fungi Aspergillus fumigates is the 
common human saprophyte among the hundreds of species A. terreus, A. 
flavus, and A. nidulans. They are heat resistant and can survive wide range 
of temperatures. They are readily demonstrated by fungal staining like 
GMS and PAS stains. Hundreds o f species have been identified. 
Commoner ones are the three species: flavus, fumigatus, niger. 
Temperature of 14° to 50°C is suitable for survival of the fungus and more 
so with in the range of body temperatuire.  
 
PATHOGENESIS 
Man gets infected once he is exposed to the wind of spores. Once 
the inspired diameter is less than 2.5 microns, it makes them fit into 
alveoli where they sprout and sporulate resulting in mycelia producing 
complex immune reaction leading on to chronic inflammation which is T 
helper 2 mediated inflammation of mucosa [2]of  the airways . During   
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the  persistent stages  it may invade  and cause invasive destruction 
.Spore load is not directly proportional to the amount of inflammation, 
because the spores only triggers  the cells of inflammation through 
cytokines , chemokines but they never invade during the initial stages. 
  The  proinflammatory  mediators like  interleukin 4RA ,manganese 
superoxide dismutase, ribosomal proteins ,serine protease  play a pivotal 
role in  attracting and recruiting peripheral eosinophilic and monocytic 
response to  the bronchial  irritation along with  enzyme 
metalloproteinase. Fungotoxin takes the task of bronchiolar damage and 
dilatation of airways producing ectatic changes. 
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Hyper immunoglobulinemia of  IgE  type is an evidence of type1 reaction. 
Type 3 reaction is witnessed by precipitins and the antigen antibody 
complex causing acute exacerbation. Type 4 reactions occur in chronic 
diseases with lymphocytic cell predominance in the inflammation. 
Interleukin 8 levels correlate with  neutrophil content of the airway. 
Mucus secretion causes chronic airway damage. Protease of the fungal 
origin causes breach in the protective bronchial mucosa allowing 
aspergillus antigen intrinsically through the mucosa. Other mediator of 
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aspergillus infection in heat shock protein. Surfactant proteins play a 
protective role. Forced expiratory minute volume changes in  the patient 
matches with the neutrophil content of bronchial secretion. 
PATHOLOGY 
Though ABPA never gives concrete evidence of the disease, 
hypertrophic dilatation of the airway ,goblet cell hyperplasia ,secretions  
pooled with inflammatory cells consisting of spores ,mycelium, 
nonseptate fungal element mucosal erosion, and basal layer thickening 
with interstital septal infiltration may be present in most patients. There 
may also be airway adaptations and diltation bronchocentric 
granulomatosis   
 
HPE section mucin deposition in the airways 
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Signs and symptoms: 
 Low grade to refractoy asthma with constellation of symptoms. 
 Low grade raise in temperature,  
 Cough which is highly productive with golden brown mucosal 
secretion  
 Breathlessness with an audible wheeze, decreased productivity and 
working capacity. Recurrence and re exacerbation of the similar 
picture in the form of refractory asthma. 
 One should have a high index of suspicion of ABPA in all cases of 
resistant asthma. 
 
LAB CRITERIA; 
1. Raise in absolute peripheral eosinophil count > 1000cells 
2. Eosinophils in sputum analysis,(Charcot Leyden crystals, 
Curschman’s spirals ,Creola bodies for asthma) presence of fungal 
filaments in 10%potassium hydroxide mount. 
3. Vanishing lung shadows often homogenous opacities of uupper 
zone  
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4. Positive sputum culture for aspergillus species in sabourads 
dextrose agar medium 
5. Skin prick test with instant response of a wheal of more than 4mm 
within a one quarter of an hour or a second delayed response 
within 8th hour of the same day . 
6. Aspergillus specific raised immunoglobulin E levels 
7. Increased serum precipitin levels   
8. Central cylindrical bronchiectesis in chronic phase of the disease 
 
 Patterson et al  stated 5 clinicoradiologial[1] stages  
Stages formed along with the laboratory critera of diagnostic 
significance only and they have less predictive value: 
 
STAGE 1  A known  asthmatic and  showing features of ABPA with the 
positive  diagnostic  criteria. Raised serum Immunoglobulin E levels and 
raised eosinophil counts with a positve intradermal skin prick test . wheal 
formation on the back ground of  X- RAY changes, in the form of upper 
and middle lobes opacity such as consolidation. Prednisolone has a crucial 
role in clinical improvement and symptomatic relief limiting exacerbations 
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significantly with remarkable x ray clearance and reduction in antibody 
titres 
 
Stage II— Remission: Reduction of symptoms due to prednisolone 
therapy, which helps in the persistence of stage I clinical entity for more 
than 6 months (if the drug is taken with good compliance till the 
scheduled time)and  do not down stage if prednisolone  removed from 
the schedule. Iimmunoglobulins remains at basal values without any rise 
or fall in titre . X- ray wise complete clearance of opacity not leaving 
residual shadows. 
  These  group of individuals may remain static or proceed to next 
step at any point of time 
 
Stage III—Exacerbation: Recurrence of asthma with rising 
immunoglobulinE titre withn new roentgenographic shadows on chest x 
ray 
 
Stage IV—Steroid-dependent asthma   
Persistence of cough and sputum, with audible rhonchi and infiltrates 
remaining in chest x ray. Symptoms and blood values of absolute 
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eosinophil counts and levels of immunoglobulins remains elevated 
.Inspite of treatment with prednisolone these people detoriate, if 
prednisolone is removed from the treatment 
 
STAGE 5 End stage: ABPAs who are undiagnosed and simply treated with 
reliever and controller treatment protocol for asthma ending up in 
parenchymal and airway destruction bronchiectasis, cavity and fibrosis. 
Yet treatable still only with prednisolone ,alone only with some amount of 
response to steroid therapy.  
A study conducted by Lee et el commented on reversibility in 
spirometry i.e. forced expiratory minute volume is > 0.8litres after 
adequate beta agonist treatment even at stage5. 
 
OTHER CLASSIFICATION- 
ABPA further classified as 3 different condition based on 
symptomatology immunological values [6] 
 
ABPA-S: Patients correlates with the clinical, immunological and blood 
values fitting into recommended  criteria  without proximal bronchiectasis 
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ABPA-CB: Patients expressing other clinical parameters and serum values 
together with the  proximal  bronchiectesis 
 
ABPA-CB-ORF: ABPA’s together with all the above said features and 
proximal bronchiectasis together with related x ray findings.They also 
have other roengtenographic features such as lung fibrosis, scars, bullous 
changes, cavity formation, and other pleural involvement  like effusions 
and thickening 
 
DIAGNOSIS 
ABPA takes place in bronchial asthma patients who are difficult to 
treat with conventional protocols and also in mucociliary dysfunction 
involving CFTR gene mutation. Difficult to treat asthma inclusive of 
possible symptomatolgy, x ray and computed tomographic imaging, 
serological positivity features with high index of suspicion to coin a 
patient as Allergic Bronchopulmonary aspergillosis. Fungal growth in 
culture media of airway secretion can be carried out. 
.  Atleast  a collection  of 5 essential features included in the criterion 
should be present to label a patient as allergic bronchopulmonary 
aspergillosis.8 Eligibilty features of clinical serological and x ray finding 
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should be present Are found  but  among those features some of them 
are mandatory and few of  them were not found and nonmandatory  
.  The nonmandatory features listed to frame the diagnosis are like, 
lung  opacity and fleeting  and vanishing shifting shadows or rised 
absolute eosinophil count are mostly found only during exacaerbation 
and initial stage 1 intensive phases of allergic bronchopulmonary 
aspergillosis only bronchiectasis, affecting the mere proximal segmental 
bronchi is a  concrete evidence of the disease which is uniformly not seen 
in ABPAs while labelling the patient as allergic bronchopulmonary 
aspergillosis or  during subsequent visits when the patient is under 
monitor and surveillance.  
It is difficult to distinguish these patients  from cystic fibrosis whicn 
presents with similar clinical , radiological , immunological features   and 
upper lobe bronchiectasis.(46,48) 
 Of late, the Cystic Fibrosis Foundation  framed a new methodology for 
differentiating aspergillosis from  those patients:49 
1. Worsening  of  symptomatology (cough with sputum, ronchi , 
restricted Working  performance and reduced lung capacity) 
2. Type 1 hypersensitivity to Aspergillus species 
3. Rised immunoglobin E concentration titre with definite cut off 
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4. Precipitin test positive for aspergillus species 
5. Radiological changes like opacities, mucus plugs or ill defined  
radiographic pictures not related  to  roentgenographic findings in 
aspergillosis may be taken as initial findings. The findings in  late 
stages may be the consequence of the recurrent infections during 
initial stages  predictive of persisstant destruction of the airways or 
parenchyma 
 
EARLY CHANGES: The initial changes affects the parenchyma and is seen  
in in almost 80-90% of ABPAs  as obscure homogenous roentgenographic 
opacity with no substantial loss in of  lung parenchymal contour, but 
confined or extensive lesion. Any area of the lung parenchyma can be 
affected but the common  part of the lung routinely affected are upper 
zones.(54) Upper zone opacities disappear once the patient coughs out 
the secretion. This is a classical and remarkable feature. Sometimes 
shadows may be shifted to remaining lobes so called migratory shadows. 
Some of them heal with persistent mucus plug identified as ‘ring 
shadows’. Plugging of the the epithelial mucus secretion that blocks the 
lumen produces uniform shadows in a skiagram. 
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X-ray showing early aspergillosis: Lung infiltrates 
 
Proximal airway changes occur in 50-70% initial periods of 
aspergillosis of ABPA. Chest roentgenographic picture shows tramtrack, 
parallel line (intact or dilated proximal airways) “toothpaste” and gloved 
digits (indicates airways thick tenacious secretion). Tramtrack opacity are 
the hypertrophied bronchial wall with a near normal luminal diameter. 
Parallel lines are the wall of both hypertrophied and ecstatic permanently 
dilated airways with increase transluminal diameter Ring shadows are of 
airways are also due the same reason.  
  Bronchoscopy and Broncheoalveolar lavage with suction removal of 
the tenacious secretion results in x ray clearance of the opacities such as 
tramtrack appearance and other evanescent opacities .In 15-30% of  
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aspergillosis patients , mucoid plugging of the proximal airway seen . If it 
is affected by mucoid plugging of large bronchus and spreads into the 3rd 
4th  order  airway toothpaste opacity is formed but if it  sequentially 
affects the 2nd  order bronchi it  forms the gloved finger markings which 
are  bronchiolar radio opacities 2-3 cm long and 5-8 cm wide branching 
distally from the hilum and filled with inflammatory exudates producing 
thick tenacious secretion .  The opacity at the hilum seen in  about 40% 
asthmatic days of Aspergillosis resembles peribronchial lymphadenopathy 
at the hilum, other resemblances are cavity, fluid shadow, widespread 
nodular opacities involving all the lobes  and watershed areas. 
Emphesematous bulla changes may rarely  be seen with the incidence of 
less than five percent while other changes range from  ten to twenty 
percent in incidence.(55). 
 
LATE CHANGES –Late pictures are due to recurrent infection recurrent 
and  inflammation. The late changes are manifested as fibrosis sparing the 
middle and lower zones affecting other areas. Fibrosis, fibrocavity 
formation, bulla rupturing into the pleura occurrence are literally terminal 
.53,54,56 
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Abnormal persistant permanent and irreversible dilatation of 
proximal airways are hallmark of aspergillosis. 
 
 
CT CHEST showing invasive aspergillosis 
 
 
But it differs in one way from the other diseases by destroying earlier 
generation of bronchi in contrast to otherway involving terminal 
bronchioles. High resolution computed tomography is the best diagnostic 
aid in picking up the central bronchiectasis , reticulonodular pattern are 
other findings madeout [5] 
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SPIROMETRY- 
Forced Expiratory minute Volume, FVC, Peak Expiratoy Flow rate and 
diffusion  lung capacities were not only applicable in selecting and 
identifying the cases but also for the prognostic prediction  and  reduction 
in above parameters is noted in resistant and steroid dependent stages of 
allergic bronchopulmonary aspergillosis .  The reversibility of obstruction> 
15 % after adequate bronchodiltation, even in stage 4 disease and  
reversibility of  more than 0.8 %  has a good prognostic 
value[6].Pulmonary function test shows both obstructive and restrictive 
pattern at the time of  asthmatic attacks  
Severity of decline in FEV1/FVC ratio is patient dependent 
variable.(59,60,61).Wide range of PFT variation is seen in aspergillosis 
starting from static function  to worsening and rapid derangement of lung 
function and as said earlier , spore colonisation load and sputum 
eosinophilia load is not directly proportionate to change in spirometric 
declination of the patients. 
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GUIDELINES TO DIAGNOSE ALLERIC BRONCHO-PULMONARY 
ASPERGILLOSIS IN AN ASTHMATIC PATIENT 
Whenever patient comes to us with the history or features of 
bronchial asthma , difficult and refractory to treatment with frequent 
exacerbations or poorly controlled asthma with or without radiographic 
evidence of  consolidation  or collapse , look for the underlying possibility 
of a trigger factor on the back ground of  the patient being an atopy 
suspect  for allergic bronchopulmonary aspergillosis. 
Do  a pulmonary function test to  assess  the reversibility and pattern of 
the disease. Do a screening skin prick test  to detect   a wheal of more 
than 3mm to  predict the tendency to produce increased IgE. 
Assess the peripheral eosinophil count and  serum IgE level if 
significant levels were found.  
Do  a high resolution computed tomography to look for CENTRAL 
BRONCHIECTESIS.  
Serial IgE levels can be used as a tool for follow up.  
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Aims of the therapy 
a. Identify and treat the cases at a early stage  to prevent recurrent 
attack 
b. sterilize  the airways and  mucosal secretion against this 
monomorphic fungus to prevent further attacks and relapse 
c. relief from the recurrent attacks of ABPA  like cough, 
breathlessness, wheezin, 
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d. to arrest the stage wise progression of disease and prevent 
permanent structural and functional damage like central 
bronchiectesis 
 
COMPONENTS OF TREATMENT 
a. Oral prednisolone  to fasten relief ,  curb inflammation and to stop 
ongoing process of airway damage 
b. Antimycotic therpy  to sterilize the fungal colonies in the sputum 
and the airways , mainly Itraconazole. 
c. Bronchodilators  and the airway hygeine 
 
STEROID THERAPY 
 Oral prednisolone therpy has become the sheet anchor during the 
initial  phases of the disease to relieve the symptom caused by injury due 
to inflammatory cytokines most efficient in decreasing the airway hyper 
responsiveness  and there by decreasing the rhonchi and accelerating the 
x ray clearence  It is most efficient by decreasing the blood eosinophil 
level and serum immunoglobulin E level. 
 Oral PREDNISOLONE  0.5 mg/kg/24hr  during initial 14 
days,tapered with same dose  on alternate days[6] for atleast 21 weeks is 
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the initial treatment.  The dose  is further reduced till immunoglobulin 
levels  becomes static , parallelly watching over the relief of the 
symptoms and a good radiological clearance of  the disease there by 
preventing exacerbation and maintaining the patient on remission phase 
and  reversal of spirometric derangements thereby increasing  working 
capacity and lung compliance.63 
 The lung function tests recommended for asthma patients must 
also be performed which may show  decreased lung volume, diffusion 
capacity or  is the nature of attack dependent.[23][17]  
STEVENS et el  studied the methodolgy of tapering the steroid level 
and its  adverse effects like glucose intolerance and adrenal  suppression 
taking into considerstion dosage schedule. 
 Prolonged  predniosolone  therapy is not adviced . If the patient is 
free of attacks for about 24 weeks he is in stage 2, the remission stage. 
Stage 4 patients may have recurrent attacks and he has to be put on 
maintainence prednisolone therapy to prevent relapse   and they will 
worsen if they were taken off steroid therapy. Patients in stage 5 will have 
poorer prognosis with  bad structural damage  predisposing repeated 
secondary infection  gram negative sepsis and not so responsive to steroid 
therapy. 
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ANTIFUNGAL THERAPY  
So many broad spectrum antifungal have been tried and failed but 
for their side effects (64). Inspite  of the other  side-effects the antifungal 
agent, Itraconazole is found to have major role in allergic 
bronchopulmoary aspergillosis .  A  four month drug trial made showed 
impressive results in steroid responsive asthma with end results  in the 
form of following criteria  with almost half the dose reduction of 
prednisone results in  
1) ¼ th  decrease in Immunoglobilin concentration a 
2) tleast ¼ increase in working capacity  
3)  an improvement of at least 25% in exercise tolerance or 
pulmonary-function tests  
 
OMALIZUMAB : 
HELE SIM PARK et al studied role of omalizumab in steroid 
responsive Allergic Bronchopulmonary Aspergilllosis  as an add on therapy 
(Cochrane Airways Group Asthma Trials Register) .There was  a good 
radiological and mycological clearance in their study (66). omalizumab 
prevents bronchial remodeling when administered along with the oral 
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steroids. Adrenal suppression associated with  steroid therapy is checked 
by the co administration of  itraconazole 200 mg/od .Treatment for a 
period of  4 months has shown  good response. No  tachyphylaxis  was 
noted  on continued treatment . Voricoazole and posconazoles has  no 
superiority over itracanazole   in the treatment of ABPA. Omalizumab 
(Anti IGE monoclonal antibody )  is also effective in refractory ABPA. 
  
BRONCHODILATORS-  
Inhalational broncho dilators  has additive role in the treatment of 
ABPA .  Bronchoscopy and bronchioalveolar lavage can relieve the 
obstruction  and can relieve the passive collapse. 
 
ROLE OF ADULT VACCINES AND ANTIBIOTICS 
Pneumococcal and human influenza vaccine should be 
administered in all patients receiving  prolonged immunosuppressive 
therapy. Anti pseudomonal and drugs against atypical bacteria have a 
definitive role in the treatment . 
 GENOMIC LINKS   
 People having polymorphisms of  Human Leukocyte antigen-DR 
and –DQ  of type 2  major histocompatibility complex , Interleukin 4 and-
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10-1082GA  mutation and  surfactant protein A2  mutation  are 
predisposed  to develop ABPA. 
The hereditary links and subsequent rise in single cell lineage aids in 
demarcating highly susceptible individuals . Omalizumab can be 
successfully used in this patients . 
  Allergic bronchopulmonary aspergillosis disease is first  reported in 
Britain and 10 years  later in  US thereafter significant mortality and 
morbidity studies have been recognised from various datas that  its 
invasive terminal pathology, these molds are survivors   in the Middlewest 
and eastern coastal areas. Aspergillus spores are common in indoors and 
outdoors. Universely spread without any restriction Aspergillus species 
are thermotolerant growing at 15° to 53°C temperatures and particularly 
grows well at 37° to 40°C which allows for sporulation in human bronchi. 
Septated hyphae of A. fumigatus are 8 to 11 μm in diameter with 
branching at 45° angles. Hyphae may be demonstrated in sputum, mucus 
plugs or sinus debris with Gomori methenamine-silver or periodic acid-
Schiff stains. 
  Aspergillosis may play  a role in cystic fibrosis and asthma.  Helper 
T- cells directed against antigen of the monomorphic fungal elements was 
demonstrated by ALAN  P KNUTSEN  in patients with cystic fibrosis and 
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asthma. The fungal antigens may trigger the inflammatory response that 
results in clinical detoriation..Other diseases caused by this mycoses are 
invasive fugal ball inside the cavity, madhura foot ,3.1.  
ABPA AND ASTHMA: 
DENNING AND WARDLAWS  et al. in their  study of atopic asthma  
found Hyper IgE and its heightened hypersensitivity  to fungal spores in 
the study population. The presence of ABPA  was  related to persistent 
intensive high grade asthma with recurrent attacks and rapid decline in 
lung volumes and capacity . 
Other  causes of fungal allergic mycoses  was  by penicilium marnefi  
,cladosporium ,candida and  Pseudoallecheria boydi .19–23 
Diagnosis of ABPA relies on the demonstration of fungal mycelium 
and peripheral blood esinophilia (>thousand cells per millimeter cube).  
Because most of the normal individuals may also harbour aspergillus in 
their respiratory tract as a part of colonization , demonstration of sputum 
fungal mycelium alone is not diagnostic of ABPA. Growing of sputum 
colonies in SDA agar is not considered as a diagnostic criteria ( 19 - 25).   
In contrast to Madura mycosis , elevated serum precipitin levels 
cannot be considered as  diagnostic of ABPA. 
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Hemmann et al. [24]  studied  levels of IgE antibody against 
recombinant A.fumigatus Asp f1, Asp f3, Asp f4, and Asp f6 antigens. They 
found out    Immunoglobulin E  directed against   Asp f4 and Asp f6 was  
remakably unique for aspergillosis.  
In Korean study, patient selection was based on Greenberger 
criteria and intradermal test done as a screening test with mycoserogical 
values. In this study he compared ABPA  patients with pre existing TB 
sequelae with controls and found poorer prognosis in those patients and 
ANTI IgE therapy is alternate to prednisolone in this group. 
Patients known to have recurrent attacks with acute asthmatic 
ABPAs  declines withsevere disability ,endangering acute attacks than 
their fellow asthma patients . They need more patient oriented therapies 
in addition to regular protocols like controllers and relievers like long 
acting beta agonist, LAMA, IHC .anti IgE ,azithromycin,  cholecalciferol 
supplements, avoidance of pollutants and overcrowding, Immunisation 
stage oriented treatment, use of crisis busters are rescues reserved for 
fulminant asthmatics.  
A study in American journal of respiratory and critical care medicine 
states that immunoglobun E sensitivity of Aspergillus fumigatus correlates 
with dampened spirometric function in asthmatics. 
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Patients with high immmunoglobulin load have decreased 
spirometric value mainly Forced Expiratory minute volume(FEV1) ranges 
from  around 80% in resistant cases, around  60% in hyerimmmune IgE 50 
to 60%  in cystic fibrosis and <35% in bronchiectasis.[1] 
 ELIAS MIR et al studied an analysis relating two spectrum Allergic 
bronchopulmonary aspergillosis and chronic bronchitis/emphysema. Both 
of these obstructive airway disease has correlative overlapping 
pathophysiology except for postbronchodilators reversibility which is 
more in asthmatics than in emphysema and chronic bronchitis  with the 
history of smoking. The study was noticed by a case scenario where a 
COPD patient found to have allergic bronchopulmonary aspergillosis 
fulfifilling criteria like skin prick test and other serological test  but the 
reversibility of the patient lung function was not so significant owing to 
the structural damage in the airways and parenchyma noticed. Patient 
initially came with respiratory symptom got improved  clinically, the 
author concluded the study by stating that some shared  pathobiology  
exist in this condition and that could be genomically related by familial 
hyperresponsiveness. 
DANNI .S.ZANDER et al in  his study compared statistical datas for 
allergic bronchopulmonary aspergillosis and patients with CFTR hereditary 
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mutation link between both the disease, in CF, defective dyenin arm in 
the mucosal lining incapacitates the patient to clear his mucus collection 
there by resulting in  secondary infection. Persistence of inhaled spores 
triggering  immunopathogenesis of the disease[4] dealt with the 
underawareness of the disease and the feasibility of identifying the  case 
is only possible if the consultant has the idea about the  profile of the 
disease, otherwise case will be submerged  with the  other asthma groups 
. Author of this article also enumerates the various manifestation and its 
clinical manifestation caused by A.fumigatus like ABPA, consolidation , 
invasive parenchymal  and  airway disease spectrum with the end results 
of Aspergilloma, Brochiectesis and so on, leading on to blood tinged 
sputum , desaturation and respiratory failure. Hypersensitivity  plays a 
major role in this disease with the risk factors, like atopy, asthma, 
pulmonary TB sequelae, primary immunodeficiency disease along with 
retroviral disease and both immunocompetent and immunosuppressed 
individual are at risk of aspergillus series  of  disease. 
 AGARWAL R et al included hereditary link with interleukins,  toll 
like receptors, tumor necrosis alpha ,human leukocyte antigen and major 
histocompatibility complex , alternate complement pathway has been 
mentioned  especially Mannose binding lectin dependent pathway  and 
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[5] the author has also dealt with late reaction to intradermal test as a 
non essential criteria.  The treatment schedule  role of prednisolone, 
azole group of antimycotic agents , biologicals like omalizumab in the 
treatment and bronchial hygiene  has a  specific mention; bronchial 
thermoplasty  has a role, whose prognosis and complications are  well  
dealt with statistical evidences. 
Cochrane et al G A T Register[15] there was  a good radiological and 
mycological clearance obtained with Itraconazole treatment by 
preventing bronchial remodeling. The prednisolone induced adrenalgland 
suppressive effect of corticosteroid therapy is checked by the co 
administration of  itraconazole. It also  acts by clearing the airways making 
the airways mold free by preventing mycelia formation and destroying 
conidiophores  if   given over 4 months. It  has  mycelia sterilizing effect  
and good response immunomodulation with no  tachyphylaxis  or drug 
resistance on continued treatment. Voricoazole and Posconazoles  gives 
no extra benefits. 
TILLIE –LEBLON et al in his study – mentioned about the universal 
nature of the spore and link CD 4 helper cells in pathogenesis. Mention 
about the cultural charecteristics in SDA media and a special mention 
about GROCCOT stain and conidiospore which triggers both cell and 
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antibody mediated chemotaxis; mold  load  is not  a deciding factor in the 
severity of the disease[9] 
 RADIN et al studied about the Host Factors comprising Gel and 
Coomb hypersensitivity response forms the main deciding factors. 
 GIBSON et al links the presence of chemotactic interleukin and 
phagocyte load and exudative sputum has proportionately worsened 
disease spectrum. 
  Radi et al –VLA-4, CCR-3 as a special role in chemotaxis [1] 
discussed the pathogenesis of the disease  along with the other novel 
chemokine and metalloprotien lysis 
GIBBSON et al studies the incidence of ABPA in the pediatric age 
group but declines to state that though allergen plays a main role it is a 
disease of middle aged [10]. There is immune tolerance and development 
of repeated sensization in the middle age group because of the chronic 
exposure. 
  PATERSON AND GREENBERGER – analysed various symptomatology 
and came out with a classification and staging as five various groups 
facilitating treatment schedule and the stages are not static for a given 
patient it may down stage without treatment or remain static and 
undergo remission  
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  LEE et al  shows reversibility of bronchospasm   after adequate 
treatment and studied about the foced expiratory minute volume 
improvement even in late stages of the disease in his trials [4] 
 Malo eval et al studied about the link between the asthma and 
Aspergillosis in respect to proximal bronchiectasis.  Incidence in asthma is 
around half of the central bronchiectasis about 31 % in ABPA. 
 NEELD GOODMAN et al using computerised tomography incidence 
ectatic changes in asthma and it is found that correlation is found in  2/3 
rd of the ABPA patients with this  terminal airway disease  association. 
ANGUS et al studied the incidence of passive collapse using HRCT 
and came out with incidence of 4% in allergic bronchopulmonary 
aspergillosis [8] other changes like pnuemothorax and calcification is seen 
in insignificant numbers  
REIFF et al compared the peripheral location in few cases of 
bronchiectesis. It is insignificant in number and not pathognomonic of 
allergic bronchopulmonary  aspergillosis  when compared to proximal air 
way disease which is the hall mark finding. 
 WARK PA et al – worked on antimycotic treatment; in certain cases 
they have immune modulatory effect besides cutting down fungal 
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reproductory and budding rate . He studied a meta-analysis of two groups 
using itraconazole and came out with the successful statistical values. 
MCCARTHI et al [16] studied the relationship with prolonged 
inhalation of spores in relation to  disease severity index  the  result  was 
not so significant since antigen is more necessary than antigenic load  by 
itself. 
STEVENS et al [17] studied about the toxic effects of antimycotic 
azoles and confirmed the safety margin with which it can be given for 
months without any noted side effect  
  MIDDLETON, CAPE BELL et al studied about the maximum[18] oral 
prednisolone for long duration  never benefits  acute attacks  of  
aspergillosis or asthmatic attacks, inferring that there are other factors 
like repeated exposure may trigger complement activation[20]thus the 
adjuvant use of  [19]antimycotic therapy has its own value in extending 
cure rate of the patients with ABPA. 
NEEDGOODMAN et al studied the usefulness of high resolution CT 
in detecting minor pathology of the respiratory system [21];it founded out 
several minor details it is the investigation of choice in bronchiectasis. 
 MACARTHY GREENBERGER et al  studied about the usefulness of 
the skin prick test immediate wheal is only common comparing with the 
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late type 4 hyper sensitivity reaction which is seen in less than 1/3rd of the 
patients. The test is predictive in all ABPA cases. 
RICKETI GREENBERGER et al studied about the absolute eosinophil 
count. Peripheral Eosinophil count has a diagnostic value together with 
the sputum eosinophil count. It is the sensitive test  along with 
chromatographic line representation of antigen antibody response   and 
raised immunoglobulin E and G titre will depict the severity of the disease 
and the levels can be used for follow up during remission and 
exacerbation. 
 
COMPLICATIONS AND PROGNOSTIC PREDICTORS 
There are only retrospective studies and the population oriented 
prospective trials are more expected and yet to come to predict the 
prognostic factors in this disease . A few number of case ends with 
scarring and fibrosis of the lung parenchyma and very few progress to 
right heart disease secondary to lung pathology and rest of the diseased 
group is nonprogresive in lung performance and working capacity even 
for a decade or more. 
 MAL et al studied and compared a five years Lung function in 
asthmatic with Allergic Broncho Pulmonary Aspergillosis and without 
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aspergillosis .The later group was performed well with good and adequate 
lung capacity than the former group with declining PEFR and  
superimposed restrictive  along with the obstructive pattern of the 
aspergillosis.  Patients with structural lung disease worsen more earlier 
than the serological ABPA groups.  At the end several inference were 
obtained, Allergic Broncho pulmonary aspergillosis is not unusual in 
chronic airway disease inspite of high prevalence this disease is diagnosed 
only in late stage  of the disease and supportive treatment  are atmost 
nessesary to culminate the progression of the disease .  In an Asthmatic 
with a chronic and refractory course, suspect aspergillosis and treat 
appropriately  according to their respective stages in which the patient 
land to us  there by doing justice to the long term asthma groups. 
 
 FEW RADIOLOGICAL REMINDERS OF ASPERGILLOSIS 
 Proximal Bronchiectasis 
 Migratory lobar pneumonia  
 Ring opacity  
 Double line opacity  
 Lobar scarring 
 Tooth paste like  opacity 
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 Honey Combing like pattern 
 Tram track opacity 
 Collapse 
 Aspergilloma with air crescent sign 
 Finger like opacity 
 Ground glass opacity 
 Tree in bud appearance 
 Reticulonodular pattern 
are the major x ray findings seen so far.  
Nevertheless one should not forget an absolutely normal chest x ray 
never rules out the disease which is the rule of thumb what we studied in 
asthma patients with or without ABPA. 
 
MEERK et  al en listed the  complications of therapy with prolonged 
immunosuppression. 
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immunosuppresion and its complications 
 Secondary bacterial or pneumocytis jeroveci infection 
 Adrenal axis suppression 
 Fungal infections   
 Gastero esophageal relux disease 
 Drug tolerance(rare) 
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MATERIALS AND METHODS 
 It was felt that we need to study a large group of asthmatic  
population  with the major aims of  diagnosing  allergic 
bronchopulmonary aspergillosis in the study group. Patients coming to 
the Medical OPD, emergency wards and asthma clinic of Rajiv Gandhi 
Governtment General hospial for Asthma related problems, atopy  and 
allegic rhinitis with frequent exacerbation are enrolled into the study.  
This  hospital is a Tertiary care centre for the urban and rural population 
in an around Chennai and neighbouring states.  
This is a programme comprising of identification, staging, treatment 
and follow up of allergic bronchopulmonary aspergillosis among the 
patients found to have resistant to conventional treatment. A previous 
Indian statistics, done using Rosenbergs criteria, among 651 pateints, 
showed that 338 found to have positivity(52%) with 89 proven by 
Rosenbergs criteria; since the entity was not focused completely to 
highlight underprevalence, hence the study was conducted in patients 
attending asthma clinic medical OPD and wards were  taken as subjects 
with sample size of 100 patients in different age groups, sex, with or 
without family history, smoking and atopy history after subjecting patient 
into pulmonary function test. With all these in mind a sample size of 100 
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patients was helpful in confidently conducting the study and priming 
them with details and help them addressing the questions in the study. 
 
Inclusion criteria: 
1. Patients with uncontrolled bronchial asthma. 
2. Patients with frequent asthma exacerbation.  
3. Patient having difficulty in tapering   inhalational steroids.  
 
Exclusion Criteria : 
1. Severely ill patients coexisting other respiratory diseases  
2. Patients with disorientation and unable to take part in the 
investigations. 
 
Study Conduct 
Number of patients: 
100 
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Methodology 
1. Obtaining informed written consent from the eligible patients or 
their legal representatives. 
2. Filling up of the semi structured questionnaire by interviewing the 
patient or his attender. 
3. Stratification of  Bronchial asthma  and Allergic Bronchopulmonary 
Aspergillosis patients according to guidelines . 
4. Laboratory investigations – Complete Blood Count, total serum IgE 
Concentration. 
5. Chest X Ray ,  
6. Absolute Eosinophil Count, Pulmonary function test,  KOH Mount, 
and Skin Prick Test  
7. Initially patients will be screened according to inclusion and 
exclusion criteria and the patients will be assessed for the risk 
factors of allergic bronchopulmonary aspergillosis  
8. Those patients who got admitted for asthma exacerbation and 
Steroid dependent asthma   will be  followed up   
9. Patients will be followed up for a period of six months first at the 
end of 15 days then at 30 days and later  at monthly intervals for a 
period of six months. 
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10. The patients will be consulted regarding any re admission for 
respiratory events and other illnesses. 
11. Statistical analysis of the collected data. 
Statistical Analysis 
Descriptive statistics would be done appropriately using patient 
characteristics and other data collected in the study. 
Statistical Methods 
 SPSS 
 Epi INFO  
 ANOVA 
 CHI SQUARE 
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Results and observations 
Population characteristics: 
Among the 100 patients included in the study after fulfilling inclusion 
criteria the following results were obtained. 40 were male asthmatics and 
60 were female asthmatics. 
Using criteria, allergic bronchopulmonary aspergillosis was 
diagnosed in 19 patients out of 100 refractory asthmatics.among them 
number of females were 11 (57.9 % ) among the total ABPAs).total 
number of male ABPAs were 8(42.1%)  
Gender 
Number of 
patients   
No. Of patients 
with ABPA  
%of ABPA 
patients  
Male 40 8 42.1% 
Female 60 11 57.9% 
P value= 0.100, statistically not significant. 
  
Gender 
Male 
Female 
SEX DISTRIBUTION 
AMONG ABPA PATIENTS 
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Comparative statistics of the ABPA positive and ABPA negative 
individuals 
List of variables ABPA positive(n=19) ABPA negative(n=81) 
Number of patients 19 81 
Mean age 34.421±10.90 36.67±9.92 
Male:female 8:11 32:49 
Duration of asthma 15.2±10.2 17.34±9.60 
Family history(no.) 17 33 
Skin prick test positive 17  0 
Mean absolute 
eosinophil count 
1322.73±458.99 288.13 
Mean IgE levels 2245±458.99 694.41±567.07 
Chest x ray Normal:12, abnormal:7 Normal 
HRCT chest Normal:12 abnormal:7 Normal 
Sputum KOH mount 10  0 
H/o atopy 14  12 
Mean pretreatment 
exacerbation 
3.52±1.17 0.90±0.63 
Mean spo2 95±3 98±1 
Mean post treatment 
exacerbation 
0.94±0.70 0.85±0.03 
Mean FEV1/FVC 0.73±0.06 0.85±0.03 
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Duration of disease: 
Duration of asthma  in 
years 
No. of ABPA patients No. of asthma patients 
5 to 10 9 72 
10 to 20 4 13 
>20 6 15 
 
 
Duration of asthma 
Duration of 
disease 
ABPA group(n=19) 
Non ABPA 
group(n=81) 
Mean(in years) 15.2 17.34 
SD 10.2 9.69 
P value = 0.39 not statistically significant  
0
10
20
30
40
50
60
70
80
5-10 YEARS 10-20 YEARS >20 YEARS
ABPA PREVALENCE 
NO. OF ASTHMA PATIENTS
NO. OF ABPA
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Family history comparison: 
Family history ABPA group(n=19) Non ABPA group(n=81) 
Positive 17 48 
Negative 2 33 
 
P value is <0.01 statistically significant 
Fisher eact test with CI of 95% by ANOVA method 
Relative risk for the above data is 4.57 
 
  
26% 
74% 
FAMILY HISTORY IN ABPA PATIENTS 
FAMILY HISTORY PRESNT FAMILY HISTORY NOT PRESENT
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Skin prick test and ABPA: 
Out of 19 patients with ABPA, 17 had positive skin prick test. 
Skin prick test ABPA group(n=19) Non ABPA group(n=81) 
Positive 17 0 
Negative 2 81 
 
 
 
P value is 0.0001 statistically very significant 
  
ABPA group Non ABPA group
Positive 89% 0%
Negative 11% 100%
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Correlation between absolute eosinophil count 
 
Absolute eosinophil count(cells/cumm) 
ABPA group(n=19) Non ABPA group(n=81) 
Mean 1322.73 288.135 
Sd 458.99 338 
 
  
 p value is o.ooo1 statistically very significant 
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Correlation between serum ige levels 
 
Ige levels(iu/dl) 
ABPA group(n=19) Non ABPA group(n=81) 
Mean 2245 694.41 
Sd 482.38 567.01 
Pvalue  <0.0001 statistically very significant 
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CORRELATION BETWEEN CT FINDING : 
CT finding ABPA(n=19) Non ABPA(n=81) 
Normal 12 81 
Abnormal 7 0 
P value  <0.0001 inference extremely significant 
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Correlation between sputum positive for spores in KOH mount 
Sputum koh ABPA(n=19) Non ABPA(n=81) 
Positive 10 0 
Negative 9 81 
P value<0.0001 is extremely signifcant 
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Correlation between history of atopy 
Atopy ABPA(n=19) Non ABPA(n=81) 
Present 14 12 
Absent 19 69 
 
 
 
P  value is < 0.0001,statistically significant 
  
ABPA NON ABPA
14 12 
19 
69 
ATOPY 
PRESENT ABSENT
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Correlation between pretreatment exacerbation 
 
ABPA wth 
exacerbation 
Non ABPA with 
exacerbation 
Average 3.52 0.90 
SD 1.17 0.63 
P value  <0.0001 inference extremely signficant  
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CORRELATION BETWEEN SPO2  
 ABPA(n=19) Non ABPA(n=81) 
Spo2 values 95±3 98±1 
P value <0.0004 statistically significant value. 
 
  
95 
98 
SPO2 VALUES
SPO2 VALUES 
NON ABPA(N=81) ABPA(N=19)
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CORRELATION BETWEEN POST TREATMENT COMPARISON OF FEV1/FVC 
 ABPA (n=19) Non ABPA(n=81) 
Mean 0.73 0.85 
SD 0.06 0.03 
P value is <0.0001 statistically significant 
 
 
  
ABPA NON ABPA
0.73 
0.85 
0.06 0.03 
FEV1/FVC COMPARISON 
MEAN SD
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CORRELATION BETWEEN POST TREATMENT EXACERBATIONS 
Post treatment 
exacerbation 
ABPA (n=19) Non ABPA(n=81) 
Average 0.941 0.11 
SD 0.70 0.31 
P value is<0.001 statistically significant 
 
 
0.941 
0.11 
Average
POST TREATMENT  EXACERBATION 
Non ABPA(n=81) ABPA (n=19)
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Comparison between pre treatment and post treatment exacerbations 
in ABPA patients 
 
 
Exacerbations (mean 
value) 
Pretreatment 3.52±1.17 
Post treatment 0.94±0.7 
 
P value<0.001, statistically significant 
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Stages of ABPA: 
Stages of ABPA No. Of patients 
ABPA ORF 5 
ABPA-CB 2 
ABPA-S 12 
 
 
ORF  other radiological feature  
CB central bronchiectasis  
S serological 
  
26% 
11% 
63% 
DISTRIBUTION OF ABPA 
ABPA ORF ABPA CB ABPA S
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Characteristics of ABPA S patients: 
Patient characteristics/variables Results/values(n=12) 
Total number  
Average age (in years) 
No. Of male patients   
No. Of female patients   
Average duration (in years) 
Family history positive  
Skin prick test positive  
Average absolute eosinophil count (cells/cu 
mm) 
Average ige value (iu/dl) 
Sputum koh positive 
History of atopy  
Mean value of exacerbation prior to treatment  
Average spo2  
History of smoking  
Average exacerbation after treatment  
Average post treatment FEV1/FVC ratio  
12 persons 
35.33+11.06  
5 out of 12  
7 out of 12  
13.95+8.6 
10out of 12 
12 out of 12 
1365.5+481.3 
2311.91+502.26  
7 out of 12 
3 out of 12 
3.3+0.88 
96%+3% 
2 out of 12 
0.833+0.71 
0.76+0.005 
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COMPARISON OF CHARACTERISTICS AMONG DIFFERENT TYPES OF ABPA 
 
 
Characteristics ABPA-S ABPA-ORF ABPA-CB P value 
Age(in years) 35.33±11.06 29.8±11.07 40.5±10.6 >0.05 
Duration(in 
years) 
13.95±8.6 16.2±13.42 21±18.38 >0.05 
Absolute 
eosinophil 
count(cells/cu 
mm) 
1365.5±481.3 1105±450.416 1610±93.3 >0.05 
Serum IgE 
level(IU/dl) 
2311±502.26 2053.4±539.19 232.5±14.84 <0.0002 
Pre treatment 
exacerbation 
3.3±0.88 3.8±1.2 4 ±0 >0.04 
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COMPARISON OF CHARCTERISTICS AMONG THE TYPES OF ABPA: 
 
Events 
TYPES OF ABPA 
P value 
Serology ORF CB 
Post 
treatment 
exacerbation 
0.833±0.71 1.2±0.83 1±0 0.63 
Spo2 96±3 96±2 92±1 0.17 
FEV1/FVC 0.761±0.05 0.70±0.05 0.67±0 0.02 
Variable  Mean 
difference 
Comparison P value Significance 
Post treatment 
exacerbation 
258.51 SEROLOGY VS ORF >0.005 No 
Spo2 2079.4 SEROLOGY VS CB <0.001 Yes 
FEV1/FVC 1820.9 ORF VS CB <0.01 Yes 
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DISCUSSION 
 
AGE AND GENDER: 
 
  In our study of 100 patients of refractory and resistant Asthma 
with difficulty to treat history, 19% of them were positive for ABPA. 
Previous Indian statistics suggest that the prevalence of ABPA is 3-4% in 
Asthmatics, of which 15% belong to the category of Steroid Sensitive 
patients. Around 3-14% of other related diseases also had ABPA.  
Around 19% of patients, which is a significant number belonging to 
various stages of ABPA, with definitive radiological evidence like 
bronchiectesis and related findings were present in our study. In our 
study the total number of ABPA-S was 12 and proximal bronchiectasis 
were 5 and mucus plugs, fibrosis were 2 in number. Our patients were 
analysed with respect to age distribution and the mean age group is 36.67 
years, which correlates with previous studies like AGARWAL et al.  
Our study shows. female were 11 in number and males were 8 in 
number. 
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By comparing male to female ratio, the relative risk is 0.091 which is not 
significantly showing gender difference, as the literature tells that there is 
no gross sex predilection, except in the extremes of ages. 
 
DURATION OF ASTHMA PERIOD 
 While linking duration of the disease in years, our study showed 
that between 5-10years there were 9 patients and between 10-20 years, 
there were 4 patients. When the duration of the illness was more than 20 
years, 6 patients had ABPA., As per our study, duration of this disease 
does not correlate with the prevalence thereby inferring chronicity and 
severity were not parallel. Correlating with the previous study, severity is 
linked with the sensitivity to pathogens and not the chronicity of the 
asthma prevalence.  
  
FAMILY HISTORY 
  Among 100 patients, 48 persons had family history of asthma. 
Among 100 selected asthmatics, 17 out of 19 persons with ABPA had 
positive family history. Thus assuming the fact that familial propensity is 
present in ABPA, and presence of hereditary causes (as discussed earlier) 
is a standing proof for their correlation. Since so many HLAs and other 
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factors were linked in previous study, a strong familial predisposition is 
present. 
 
ATOPY HISTORY: 
 Atopy in the study group is significantly associated with the 
predilection of ABPA. 14 out of 19 patients are atopic individuals which is 
coherent with the previous study correlating with the subtypes. 2 out 2 
persons with central bronchiectasis are atopic individuals where as atopic 
history is absent in 3 out of 12 asthmatics . In the non ABPA asthmatics 
only 12 out of 81 patients are atopic which has a negative predictive 
value.  
 
SMOKING HISTORY: 
 Only 3 persons out of 19 ABPA patients were smokers, thus 
suggesting that risk of smoking is not significant in the pathobiology of 
ABPA as in COPD, but immune dysregulation has still has a role in cause. 
 
SKIN INTRADERMAL TEST: 
  The study group was analyzed with intradermal test, which is more 
are less a screening test. The test showed 17 out of 19 ABPA were positive 
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for skin prick test. On the other group (non ABPA group), skin prick test 
was negative in all the individuals. With this significance, our study has 
showed remarkable association of skin prick test in predicting the 
prevalence of ABPA. 
 
ABSOLUTE EOSINOPHIL COUNT: 
 In our study the average value is 1322.73 cells/cu mm. On the other 
group (non ABPA) average value is 288.135  
Eosinophil count has more relevance in establishing the ABPA 
diagnosis. The number of eosinophils counts has pivotal role in the 
diagnosing ABPA case among the asthmatics. Comparing with the 
previous study conducted by Greenberg Paterson et al, which shows 
similar results, the role of eosinophils in diagnosing ABPA is re 
emphasized.  
 
SERUM IMMUNOGLOBULIN E level: 
  Among the ABPA diagnosed, 2245.48 IU/dl is the average value of 
IgE levels. Comparing with the non ABPA groups patients, who were 
found to have lesser levels of statistical significance. Group of patients 
with high IgE levels were found to have no predilection to gender. But it 
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has correlation to severity of disease and severity of radiological 
manifestations.  
 
RADIOLOGY: 
  Chest X- Ray and the CT chest have definite value in diagnosing 
ABPA. ABPA with proximal bronchiectasis was present in 2 out of 19 
patients. Proximal bronchiectasis has more specific value, than the other 
types of bronchiectesis. No abnormal imaging pattern was present in the 
non ABPA group (81 patients). Abnormal finding was present in 7 out of 
19 patients in the ABPA group. 
 
OXYGEN SATURATION SPO2 : 
  Most of the ABPA patients in our study group were maintaining 
good saturation except for those with severe structural lung disease. But 
it has limitations in its comparative value, among the ABPAs. 
 
TYPES OF ABPA: 
Of the 3 types of ABPA identified in our study, ABPA S was the most 
commonly identified type. 
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EXACERBATION REDUCTION: 
 Exacerbation is one of the serious clinical manifestation in patients 
with ABPA. As per our study, pretreatment exacerbation average was 
3.52. Compared with non ABPA group, it was statistically significant. In 
patients with ABPA, exacerbations before and after treatment were 
compared. The number of exacerbations reduced drastically in this group 
of 19 patients. Hence, treatment with prednisolone and itraconazole in 
reducing the exacerbations is identified. ALIF et al correlates ABPA with 
the frequency in exacerbation.  
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CONCLUSION: 
 
1. The prevalence of allergic Bronchopulmonary aspergillosis in the 
treatment resistant Bronchial Asthma patients was 19% percentage 
in this study and it is comparatively little higher  than the previous 
studies conducted. 
2. Positive family history, history of atopy and history of recurrent 
exacerbations were identified as risk factors among the study 
group. 
3. Complications like bronchiectasis and parenchymal damage, was 
seen in significant number among the study groups.  
4. Duration of Asthma and severity has no direct link between each 
other. 
5. Skin prick test is a good screening test to identify ABPA patients 
among asthmatics. 
6.  Sputum test for potassium Hydoxide mount has shown good 
number of positive results but cannot be used as a screening test. 
7.  Blood values of eosinophils and IgE antibody levels highly correlate 
with ABPA positivity among asthma patients. 
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8. Significant differences in lung function were observed between 
ABPA and non ABPA groups. 
9. Exacerbations are reduced after treatment in good number of 
patients, efficacy of prednisolone and Itraconazole, are highly 
reliable and test outcome has good. 
In refractory cases of asthma, ABPA must be considered as possible 
diagnosis. 
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ABBREVIATIONS 
 
ABPA                                           ALLERGIC BRONCHOPULMONARY 
       ASPERGILLOSIS 
BA                                               BRONCHIAL ASTHMA 
SPT                                              SKIN PRICK TEST 
AEC                                             ABSOLUE EOSINOPHIL COUNT 
AE                                                ACUTE EXACERBATIONS 
FEV1                                            FORCED EXPIRATORY MINUTE VOLUME 
FVC                                             FUNCTIONAL VITAL CAPACITY 
ABPA-S                                      SEROLOGICAL TEST POSITIVE 
ABPA-CB                                   CENTRAL BRONCHIECTASIS 
ABPA-ORF                                 OTHER RADIOLOGICAL FEATURES 
GMS                                            GOMARRI METHANAMINE SILVER 
PAS                                             PERIODIC ACID STAIN 
PEFR                                           PEAK EXPIRATORY FLOW RATE 
CF     CYSTIC FIBROSIS 
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PROFORMA 
 
Name:                                                       Age:                   Sex: 
Education: 
Address: 
Unit/Ward: 
ID number:     
INFORMANT  : Self / Other   RELATION 
 
PRESENT HISTORY 
Day of onset of the symptoms 
 Time of onset of the symptoms 
 Treatment obtained prior to admission 
 
PAST and PERSONAL HISTORY  
Bronchial Asthma                                            ONSET/DURATION 
Diabetes Mellitus    Yes / No  Duration 
Hypertension    Yes / No  Duration 
Pulmonary TB     Yes / No  Duration 
Atopy                            Yes / No  Duration 
COPD                 Yes / No  Duration 
Bronchiectesis                          Yes / No  Duration 
 
Dyslipidemia    Yes / No  Duration 
Alcoholism     Yes / No  Duration 
Smoking     Yes / No  Duration 
Medications 
 
FAMILY HISTORY 
            Hypertension                                                 Yes/No                         
Duration 
            Diabetes                                                          Yes/No                         
Duration 
            Coronary artery disease                               Yes/No                         
Duration 
COPD                       Yes / No  Duration 
Bronchial Asthma                     Yes / No  Duration 
 
PREGNANCY/PUERPERIUM AT PRESENT              Yes /No 
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VITALS 
Pulse rate   : /min 
Blood Pressure  : 
 / mm Hg Limb: RUL / LUL Posture: /sitting / 
Supine 
Respiratory Rate  : /mt 
ANTHROPOMETRY 
 Height    : m 
 Weight   : kg 
 BMI    : kg / m2 
 Waist Hip Ratio 
 
CVS    : 
 
Respiratory system  : 
 
Abdomen examination : 
 
CNS examination  : 
 
INVESTIGATIONS: 
COMPLETE HEMOGRAM 
Hemoglobin   : g/dL 
Total Count   : cells/cu.mm 
Differential count                 : 
RBC Count                              :           cells/cu.mm 
Platelets   : lakhs/cu. mm 
BLOOD BIOCHEMISTRY 
Random Blood Sugar : mg/dL 
Blood Urea   : mg/dL 
Serum Creatinine  : mg/dL 
            Serum sodium                        :           meq/l 
           Absolute Eosinophil count  :          dl/bld. 
         Skin Prick Test : + / -   
LIVER FUNCTION TESTS 
1. Total bilirubin                    :           mg/dl.    
2.  AST                                     :           IU/L. 
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3. ALT                                      :             IU/L. 
4. Total proteins                    :            grams/dL. 
5. Albumin                              :            grams/d 
 
CHEST XRAY    
 
PULMONARY FUNCTION TEST 
 
SERUM  IGE LEVEL 
 
PEAK EXPIRATORY FLOW RATE 
 
 CT CHEST 
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1 Raja 43 M 23 Y Y 1879 2543 N N Y ABPA-s y 3 0.99 yes 1 0.68 
2 Alima 40 F 40 N N 87 246 N N N N y 1 0.98 no 0 0.81 
3 chellammal 36 F 10 Y Y 1500 1675 N N N N n 1 0.99 no 0 0.82 
4 saravanan 30 M 5 N N 97 453 N N N N n 1 0.99 yes 0 0.88 
5 sandhya  18 F 5 Y Y 1660 2300 N N Y ABPA-s n 3 0.96 no 1 0.68 
6 kanaga 33 F 8 N N 900 1100 N N N N n 1 0.98 no 0 0.72 
7 jothi 30 F 25 Y N 350 560 N N N N y 1 0.98 no 0 0.86 
8 susila 30 F 6.5 Y Y 800 1900 N N Y ABPA-S y 4 0.96 no 0 0.78 
9 sarasu  45 F 22 N N 64 54 N N N N n 1 0.99 no 0 0.88 
10 meenakshi 50 F 28 N N 344 566 N N N N n 1 0.98 no 0 0.86 
11 vijaya 48 F 34 Y Y 1544 2333 B B Y ABPA-CB y 4 0.92 no 1 0.67 
12 chinnathabi  32 M 6 N P 1023 2500 N N P ABPA-S y 2 0.91 yes 0 0.75 
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13 jayammal 29 F 23 N N 234 409 N N N N n 1 0.94 no 0 0.81 
15 vijaya  16 F 9 N N 60 445 N N N N n 2 0.99 no 0 0.86 
16 kanniyammal 50 F 23 Y Y 2166 3465 N N N ABPA-S n 4 0.91 no 2 0.86 
17 sarasu  35 F 3 N N 45 456 N N N N n 1 0.98 no 0 0.86 
18 sanjammal 45 F 38 Y N 890 1656 FB FB N ABPA -ORF n 5 0.97 no 2 0.72 
19 kasthuri 42 F 34 N N 54 345 N N N N n 1 0.99 no 0 0.88 
19 nagappan 34 M 8 Y Y 1600 2300 FB FB N ABPA-ORF y 6 0.97 yes 2 0.79 
20 kamala 60 F 20 N N 56 233 N N N N n 0 0.99 no 0 0.88 
21 pandammal 40 M 29 N N 23 321 N N N N n 1 0.98 no 0 0.88 
22 sathyavathi  25 F 20 Y Y 440 1432 FB FB Y ABPA-ORF n 1 0.92 no 0 0.71 
23 logammal 49 F 10 N N 60 154 N N N N y 1 0.99 no 0 0.85 
24 dhanam 44 F 39 N P 550 1453 N N N N n 1 0.97 no 1 0.82 
25 gopalan  33 M 8 Y Y 1676 2312 B B Y ABPA-CB y 4 0.91 no 1 0.67 
26 krishnan 42 M 29 Y N 45 243 N N N N n 1 0.98 yes 1 0.88 
27 kumar 45 M 15 N N 56 342 N N N N n 1 0.96 yes 0 0.86 
28 beevi 40 F 18 N N 67 182 N N N N n 1 0.97 no 0 0.88 
29 kamala   60 F 14 N N 109 388 N N N N y 1 0.99 no 0 0.87 
30 pandamml 40 F 5 Y Y 1561 2387 N N N ABPA-S n 5 0.99 no 1 0.72 
31 padma 30 F 5 Y Y 1256 2800 FB FB N ABPA-ORF y 3 0.96 no 1 0.67 
32 venkat 22 M 10 Y Y 908 1300 N N N N y 1 0.92 yes 0 0.81 
33 raja 45 M 35 Y Y 1243 2456 N N N N y 3 0.96 yes 0 0.83 
34 azarudeen 18 M 4 Y N 67 330 N N N N n 1 0.99 no 0 0.84 
35 sendurkani 40 M 5 N N 78 800 N N N N n 1 0.98 yes 0 0.88 
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36 muniammal 35 F 5 Y N 134 454 N N N N n 1 0.98 no 0 0.87 
37 durairaj 55 M 6 N N 45 220 N N N N n 1 0.99 no 1 0.85 
38 vijay kumar 15 M 10 Y N 1340 2079 MC MC Y ABPA-ORF y 4 0.96 no 1 0.65 
39 mythili 41 F 14 Y Y 60 1338 N N N N y 1 0.97 no 0 0.81 
40 rajammal 47 F 22 Y Y 1100 2079 N N N N y 3 0.97 no 0 0.83 
41 nagappan 39 M 6 N N 65 133 N N N N n 1 0.98 no 0 0.91 
42 hemavathy 34 F 12 N N 167 657 N N N N n 1 0.98 no 0 0.89 
43 raja 16 M 10 N N 1167 2345 N N P N n 1 0.99 no 0 0.81 
44 vinoth 29 M 12 Y Y 1450 2453 N N Y ABPA-S y 4 0.93 no 1 0.81 
45 revathi 28 F 7 Y N 67 342 N N N N n 1 0.98 no 1 0.89 
46 rani 34 F 18 N N 453 1776 N N N N n 2 0.99 no 0 0.86 
47 anbalagan 56 M 30 N N 344 1221 N N N N n 5 0.99 no 0 0.84 
48 fathima 43 F 17 N N 122 309 N N N N n 2 0.98 no 0 0.89 
49 parimala 28 F 12 Y Y 1600 2335 N N N ABPA-s y 3 0.97 no 0 0.78 
50 kavitha 28 F 15 N N 213 322 N N N N n 1 0.99 no 1 0.82 
51 keerthana 24 F 2 N N 342 768 N N N N n 1 0.97 no 0 0.87 
52 yasodha 54 F 35 N N 45 769 N N N N n 1 0.99 no 0 0.86 
53 ramani 42 F 13 Y Y 456 1324 N N N ABPA-s y 4 0.98 no 1 0.81 
54 pratheep 27 M 17 N N 56 432 N N N N n 1 0.98 no 0 0.89 
55 karthick 27 M 5 N N 74 452 N N N N n 1 0.99 no 0 0.87 
56 sudhakar 32 M 23 N N 132 700 N N N N n  1 0.99 yes 0 0.84 
57 suresh 34 M 7 N N 220 346 N N N N n 1 0.99 yes 0 0.86 
58 valli 43 F 23 N N 120 122 N N N N n 0 0.98 no 0 0.84 
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59 sumathi 36 F 20 N N 210 654 N N N N n 0 0.98 no 0 0.89 
60 sivagami 32 F 21 N N 225 153 N N N N n 0 0.99 no 0 0.88 
61 vijayaragav 45 M 23 Y N 45 344 N N N N n 0 0.98 yes 0 0.91 
62 sathyavathi  24 F 20 Y Y 1564 2314 N N N N y 2 0.99 no 1 0.79 
63 parthioban 39 M 12 N N 231 453 N N N N n 1 0.97 no 0 0.88 
64 sundar 36 M 28 N N 69 153 N N N N n 0 0.98 no 0 0.86 
65 venkatram 47 M 23 Y Y 1567 2343 N N N ABPA-s y 3 0.97 no 2 0.76 
66 prabakar 36 M 13 N N 342 674 N N N N n 1 0.99 yes 0 0.84 
67 usha 31 F 18 N N 456 1643 N N N N n 2 0.98 no 0 0.81 
68 natraj 45 M 30 N N 560 1430 N N N N n 2 0.98 no 0 0.91 
69 ranjith 18 M 9 Y Y 1004 1882 N N N ABPA -s y 2 0.99 no 0 0.82 
70 hari 38 M 4 Y N 322 342 N N N N n 1 0.99 no 0 0.84 
71 naveen 16 M 9 N N 67 1323 N N N N n 2 0.98 no 0 0.83 
72 alamelu 37 F 5 N N 89 323 N N N N n 1 0.97 no 0 0.82 
73 perumal 42 M 22 N N 54 784 N N N N n 0 0.98 no 0 0.79 
74 vasanta 36 F 24 N N 57 565 N N N N n 0 0.99 no 0 0.82 
75 chandra 57 F 30 N N 343 435 N N N N n 0 0.98 no 0 0.91 
76 arjunan 35 M 19 N N 563 1121 N N N N n 3 0.97 yes 0 0.81 
77 arundathi 22 F 17 Y N 476 1354 N N N N y 4 0.98 no 1 0.79 
78 kokila 38 F 10 Y N 56 332 N N N N y 1 0.97 no 0 0.88 
79 rani 38 F 4 Y N 480 1334 N N N N n 2 0.98 no 1 0.86 
80 preethi  17 F 4 Y N 440 1034 N N N N y 2 0.96 no 0 0.88 
81 iyappan 32 M 23 N N 561 1181 N N N N n 1 0.98 yes 0 0.81 
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82 nagaraj 40 M 17 N N 459 1068 N N N N n 1 0.98 yes 0 0.85 
83 puspa 25 F 12 Y N 43 453 N N N N n 0 0.97 no 0 0.82 
84 moorthy 31 M 20 N N 67 234 N N N N n 0 0.99 yes 0 0.84 
85 chellapa 45 M 25 N N 56 122 N N N N n 0 0.99 yes 0 0.84 
86 bakiam 45 F 8 N N 70 124 N N N N n 0 0.99 no 0 0.91 
87 dhanalaksmi 25 F 19 N N 89 234 N N N N n 0 0.98 no 0 0.81 
88 mary 47 F 35 Y N 65 206 N N N N n 0 0.98 no 0 0.86 
89 ragini 40 F 29 Y N 60 105 N N N N n 0 0.98 no 0 0.87 
90 laksmi 36 F 8 N N 78 243 N N N N n 1 0.94 no 0 0.81 
91 poongothai 47 F 30 N Y 1220 2311 N N P ABPA-s y 3 0.95 no 1 0.69 
92 kamaksi 36 F 15 N N 112 344 N N N N n 2 0.98 no 0 0.81 
93 jeya 38 F 23 N N 667 980 N N N N n 1 0.98 no 0 0.84 
94 durai 41 M 9 N N 230 650 N N N N n 1 0.97 yes 0 0.84 
95 annamalai 38 M 25 Y N 69 230 N N N N n 0 0.99 no 0 0.83 
96 senthilkumar 26 M 18 N N 430 789 N N N N n 0 0.98 no 0 0.81 
97 mariyal 39 F 29 Y N 675 1221 N N  N N n 3 0.98 no 1 0.72 
98 pryadarsini 24 F 15 N N 450 900 N N N N n 1 0.99 no 0 0.88 
99 lillibai 35 F 5 N N 239 560 N N N N n 1 0.98 no 0 0.86 
100 amirtha 40 F 28 Y N 347 543 N N N N n 1 0.98 no 0 0.82 
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